1246816-75-0

• 常用中文名：盐酸莫西沙星-13CD3
• 常用英文名：Moxifloxacin-d3-1 hydrochloride
• CAS号：1246816-75-0
• 分子式：C₂₁H₂₂D₃ClFN₃O₄
• 分子量：440.91
• 相关类别： 研究领域 感染
• 发布时间：2016-03-12 21:56:22
• 更新时间：2024-01-10 11:22:24
• 盐酸莫西沙星d3-1(BAY 12-8039-d3-1)是氘标记的莫西沙星(HY-66011A)。莫西沙星是一种口服活性8-甲氧基喹诺酮类抗菌药物,用于治疗急性细菌性鼻窦炎、慢性支气管炎急性细菌性加重和社区获得性肺炎[1][2][3]。

名称

• 中文名: 盐酸莫西沙星-13CD3
• 英文名: 7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-4-oxo-8-(trideuteriomethoxy)quinoline-3-carboxylic acid,hydrochloride
• 英文别名: Actira-13CD3; Proflox-13CD3; 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic Acid-13CD3 Hydrochloride; Avalox-13CD3; Moxifloxacin Hydrochloride-13CD3; BAY-12-8039-13CD3

物化性质

• 分子式: C₂₁H₂₂D₃ClFN₃O₄
• 分子量: 440.91
• 精确质量: 441.17400
• PSA: 83.80000
• LogP: 3.56630

生物活性

• 描述: 盐酸莫西沙星d3-1(BAY 12-8039-d3-1)是氘标记的莫西沙星(HY-66011A)。莫西沙星是一种口服活性8-甲氧基喹诺酮类抗菌药物,用于治疗急性细菌性鼻窦炎、慢性支气管炎急性细菌性加重和社区获得性肺炎[1][2][3]。
• 相关类别:
  研究领域 >> 感染
• 体外研究: 氢、碳和其他元素的稳定重同位素已被纳入药物分子中,主要作为药物开发过程中定量的示踪剂。氘化引起了人们的关注,因为它可能影响药物的药代动力学和代谢谱[1]
• 参考文献:

  [1]. Culley, C.M., et al., Moxifloxacin: clinical efficacy and safety. Am J Health Syst Pharm, 2001. 58(5): p. 379-88.

  [2]. Balfour JA, et al. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs. 2000 Jan;59(1):115-39.

  [3]. Grayo S, et al. Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against Listeria monocytogenes. Antimicrob Agents Chemother. 2008 May;52(5):1697-702.

  [4]. Ioannidis O, et al. Effect of moxifloxacin on survival, lipid peroxidation and inflammation in immunosuppressed rats with soft tissue infection caused by Stenotrophomonas maltophilia. Microbiol Immunol. 2014 Feb;58(2):96-102.

  [5]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-246.